Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Retained Earnings data on file, last reported at -$1.2 billion in Q1 2026.

• Quarterly Retained Earnings fell 17.97% year-over-year to -$1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 17.97% YoY) and the FY2025 annual result came in at -$1.1 billion, down 626563.89% from the prior year.
• Retained Earnings declined to -$1.2 billion in Q1 2026, from -$1.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $302000.0 in Q4 2023 to a low of -$1.2 billion in Q1 2026.
• A 5-year average of -$651.1 million and a median of -$701.2 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 2128020.0% — and 2023, when it soared 100.07%.
• Tracing SYRE's Retained Earnings over 5 years: stood at -$425.6 million in 2022, then soared by 100.07% to $302000.0 in 2023, then sank by 40.4% to $180000.0 in 2024, then sank by 626563.89% to -$1.1 billion in 2025, then slipped by 6.42% to -$1.2 billion in 2026.
• The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), -$1.1 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.